Northwestern Mutual Wealth Management Co. Takes $68.88 Million Position in IQVIA Holdings Inc. $IQV

Northwestern Mutual Wealth Management Co. bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, HoldingsChannel.com reports. The fund bought 356,505 shares of the medical research company’s stock, valued at approximately $68,884,000.

Other large investors also recently added to or reduced their stakes in the company. International Assets Investment Management LLC purchased a new stake in IQVIA during the fourth quarter valued at about $27,000. Gilpin Wealth Management LLC purchased a new position in shares of IQVIA in the fourth quarter worth about $27,000. CrossGen Wealth LLC bought a new stake in shares of IQVIA in the 4th quarter valued at about $28,000. Activest Wealth Management lifted its stake in shares of IQVIA by 590.0% in the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 118 shares during the last quarter. Finally, Financial Freedom LLC bought a new position in IQVIA during the 1st quarter worth approximately $25,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV stock opened at $260.17 on Friday. The firm has a market capitalization of $42.82 billion, a price-to-earnings ratio of 32.28, a PEG ratio of 2.21 and a beta of 1.18. The stock has a fifty day moving average of $213.32 and a 200 day moving average of $187.52. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $260.40. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same period in the prior year, the business earned $2.81 EPS. The company’s revenue for the quarter was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, research analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA announced that its Board of Directors has authorized a stock buyback program on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

IQV has been the subject of several recent research reports. William Blair upgraded IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. JPMorgan Chase & Co. lifted their target price on shares of IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Mizuho upped their price target on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Barclays reissued an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. Finally, Robert W. Baird upped their price objective on shares of IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $241.88.

Insider Activity at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider owned 2,989 shares in the company, valued at approximately $732,932.69. This represents a 15.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider W Richard Staub sold 5,500 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the transaction, the insider directly owned 13,312 shares of the company’s stock, valued at $3,097,436.16. This represents a 29.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 12,913 shares of company stock valued at $3,098,793 in the last three months. Corporate insiders own 1.70% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.